OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
/PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology,...
Tomoyuki Miyabayashi Asahi Kasei Group Business Development Division Head Of Research Technology Ventures University Of Tokyo Edge Capital Partners
Source: prnewswire.com